Viking Therapeutics, Inc.
Viking Therapeutics, Inc. scores highest on Anchor (60) and lowest on Price (9). Its PosiPenta is 36.21 out of 100, weaker than most similar companies.
On the Penta Grid this week, Viking Therapeutics, Inc. is Grid #641 of 837 in the Healthcare sector in United States, and Grid #3,202 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Viking Therapeutics, Inc. | 36.21 | 9 | 21 | 38 | 54 | 60 |
| Parabilis Medicines, Inc. | 42.70 | 23 | 39 | 31 | 60 | 60 |
| Celcuity Inc. | 31.42 | 0 | 47 | 33 | 4 | 72 |
| Tarsus Pharmaceuticals, Inc. | 49.45 | 7 | 53 | 70 | 54 | 62 |
| Warby Parker Inc. | 54.64 | 10 | 87 | 75 | 52 | 49 |
| IDEAYA Biosciences, Inc. | 44.36 | 24 | 20 | 72 | 67 | 40 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.39 |
| P/B ratio | 7.84 |
EEarnings
| Trailing EPS | ₹-442.32 |
| Forward EPS | ₹-412.56 |
NNitro
| Price | 2383.98 |
| 52-week high | 4086.95 |
| 52-week low | 2362.19 |
| Fall from 52-week high | 41.7% |
TTorque
| Return on equity (ROE) | -88.85% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | 0.65 |
| Market cap | ₹30,315 Cr |
| Insider holding | 2.84% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Viking Therapeutics, Inc.'s PosiPenta score?
Viking Therapeutics, Inc.'s PosiPenta is 36.21 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Viking Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Viking Therapeutics, Inc. is Grid #641 of 837 in the Healthcare sector in United States, and Grid #3,202 of 4,000 in United States.
Which PosiPenta pillar is strongest for Viking Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 60 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Viking Therapeutics, Inc.?
Price (valuation), with a score of 9 out of 100: much weaker than most similar companies.
Has Viking Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 9.79 points, from 26.42 to 36.21.
PositoAI is for research and education only and is not investment advice.